



# Effectiveness of Spiritist “passe” (Spiritual healing) for anxiety levels, depression, pain, muscle tension, well-being, and physiological parameters in cardiovascular inpatients: A randomized controlled trial<sup>☆,☆☆</sup>



Élida Mara Carneiro<sup>a,b,c,\*</sup>, Luana Pereira Barbosa<sup>b</sup>, Jorge Marcelo Marson<sup>b</sup>, Juverson Alves Terra Junior<sup>b</sup>, Claudio Jacinto Pereira Martins<sup>b</sup>, Danielle Modesto<sup>b</sup>, Luiz Antônio Pertili Rodrigues de Resende<sup>b</sup>, Maria de Fátima Borges<sup>a,b,c</sup>

<sup>a</sup> Committee on Religious and Spiritual Assistance (CARE), Brazil

<sup>b</sup> Hospital de Clínicas de Uberaba, Universidade Federal do Triângulo Mineiro (Federal University of Triângulo Mineiro), Rua Getúlio Guaritá, 330, 38025-440 Uberaba, MG, Brazil

<sup>c</sup> Medical Spiritist Association (AMEUBE), Praça Dr. Thomaz Ulhôa, 50, 38025 050 Uberaba, MG, Brazil

## ARTICLE INFO

### Article history:

Received 22 July 2016

Received in revised form 24 October 2016

Accepted 23 November 2016

Available online 24 November 2016

### Keywords:

Spiritual healing

Energy therapies

Therapeutic touch

Complementary therapies

Anxiety

Depression

Coronary artery disease

## ABSTRACT

**Background:** Biofield therapies, such as laying on of hands, are used in association with Conventional Medicine as Spiritist “passe”, among others. The aim of this study was to evaluate anxiety, depression, pain, muscle tension and well-being, as well as physiological parameters in cardiovascular inpatients submitted to the Spiritist “passe”, sham, and no intervention.

**Methods:** In the total, 41 cardiovascular inpatients submitted to the Spiritist “passe”, sham, and no intervention during a 10-min period on 3 consecutive days. They were evaluated through anxiety and depression level, pain, the perceptions of muscle tension and well-being and physiological parameters, before and after interventions.

**Results:** A significant reduction ( $p=0.001$ ) in anxiety scores and muscle tension ( $p=0.011$ ), improvement of well-being ( $p=0.003$ ) and a significant increase in peripheral oxyhemoglobin saturation scores ( $p=0.028$ ) were observed in Spiritist “passe” patients, and a significant reduction ( $p=0.028$ ) of muscle tension and improvement of well-being ( $p=0.045$ ) in sham patients. However, muscle tension reduction ( $p=0.003$ ) and improvement of well-being ( $p=0.003$ ) were more accentuated in the Spiritist “passe” compared to sham and no intervention.

**Conclusions:** Results suggest that the Spiritist “passe” appeared to be effective, reducing anxiety level and the perception of muscle tension, consequently improving peripheral oxyhemoglobin saturation and the sensation of well-being compared to sham and no intervention in cardiovascular inpatients.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

The presence of psychiatric disorders such as depression and anxiety not only contributes to functional deficits in patients with coronary artery disease,<sup>1</sup> but also represents an additional important risk factor. In addition, depression and anxiety have

proved to be predictive factors of low adherence to pharmacological treatment.<sup>2</sup> Patients with rheumatoid arthritis, arterial hypertension, lower back pain and heart diseases frequently report depressive symptoms as a comorbidity.<sup>3–5</sup>

Multicenter investigations denoted ENRICHD (Enhancing Recovery in Coronary Heart Disease) have reported the presence of depressive disorders in 30–50% of patients with acute coronary syndrome (ACS).<sup>6</sup> Among patients with coronary artery disease, the prevalence of anxiety disorders is approximately 24%.<sup>7</sup>

Complementary and alternative medicine (CAM), despite a distinct philosophical conception, are used in association with conventional medicine, and have been increasing in significance worldwide since the late 1970s.<sup>8,9</sup> Approximately 40% of the United States population has used some type of complementary therapy.<sup>10</sup>

<sup>☆</sup> Research approved by the Ethics Committee in Research of the Federal University of Triângulo Mineiro (UFTM), under number 1.040.905 and all the participants signed the Free and Clarified Consent Term.

<sup>☆☆</sup> Register clinical trial: NCT02489136

\* Correspondence to: Medical Spiritist Association (AMEUBE), Praça Dr. Thomaz Ulhôa, 50, 38025 050 Uberaba, MG, Brazil.

E-mail address: [elidamc16@gmail.com](mailto:elidamc16@gmail.com) (É.M. Carneiro).

In Brazil, one of the most used CAM is energy therapy also known Spiritist "passe", which has been used in several clinical conditions, including depressed patients.<sup>11</sup> The Spiritist "passe" results in an exchange of fluids and energies derived from the Spiritist healer, from good Spirits or from a combination of both.<sup>23</sup> However the studies that evaluate the effects of this energy therapy on the physical and mental health is still scarce in the scientific literature.

The objective of the present study was to assess the levels of anxiety, depression, pain, perceptions of muscle tension (TM) and well-being (BE) and physiological parameters (PP) in cardiovascular inpatients submitted to the Spiritist "passe" group (SP), sham group (HG) and control group (CG).

## 2. Methods

### 2.1. Study design and participants

This was a randomized controlled trial, conducted at the University Hospital, Federal University of Triângulo Mineiro (UFTM), on cardiovascular inpatients aged 18 years or older. Patients undergoing psychiatric care for anxiety or depression, neurological deficits, and those with less than 2 days and more than 60 days of hospitalization were excluded. All patients received psychological treatment.

### 2.2. Experimental procedures

For group assignment, patients were numbered consecutively using Microsoft Excel, which generated a sequence of randomized numbers.

The 41 patients were included to CG, SP and HG. During 10-min sessions held on 3 consecutive days, the participants of all three groups lay in dorsal decubitus. HG and SP subjects were instructed to direct their thoughts at Jesus with wishes of healing during the intervention, which was witnessed by a research assistant. CG patients lay for 10 min receiving no intervention.

In the SP and HG, the healers and volunteers moved their hands in a longitudinal direction, starting at the top of the patient's head and slowly sliding their hands along the body of the patient<sup>12</sup> for 5-min. Then, they laid their hands over the patient with their left hand over their head and their right hand over their chest, at a distance of approximately 10–15 cm<sup>13</sup> for 5-min.

The Spiritist healers were allowed to prepare by praying prior to the session and they were having at least 2 years of experience. In the HG, volunteers of the hospital that not to be a practitioner of the Spiritist religion were recruited and trained as sham healers transmitting sincere wishes of improvement to the patients by thought (nonspiritual therapy). All being older than 18 years.

Data collection was carried out in the period from October 2014 to March 2015, totaling of 66 cardiovascular inpatients.

The study was blind, meaning that the professionals who participated in the application of the scales or performed statistical analysis, as well as patients of the SP and HG groups were not aware of which treatments the patients had received.

### 2.3. Measures

The Hospital Anxiety and Depression (HAD) scale were carried out at baseline (D1) and after the interventions on day 3 of treatment (D3). In addition, the evaluations of the pain VAS, of TM and BE, and of PP occurred out at baseline on the day 1 (D1), on day 2 (D2) and on day 3 (D3), before and immediately after the interventions.

**Table 1**  
Clinical diagnosis of the patients (n = 41) in the groups studied.

Clinical diagnosis	Control n (%) <sup>*</sup>	SP	Sham
ACS	4 (30.7)	9 (64.3)	5 (35.7)
HD	3 (23.1)	1 (7.1)	6 (42.9)
DC	3 (23.1)	1 (7.1)	1 (7.1)
IE	2 (15.4)	2 (14.3)	0 (0.0)
Others	1 (7.7)	1 (7.1)	2 (14.3)

SP, Spiritist "passe"; ACS, acute coronary syndrome; HD, hypertensive disease; DC, dilated cardiomyopathy; IE, infectious endocarditis.

\* There were no differences between groups in scores for the clinical diagnosis ( $p=0.258$ ).

### 2.4. Assessment of anxiety and depression

The HAD scale was validated Portuguese by Botega et al.<sup>14</sup> The HAD comprises 14 items subdivided into two scales, measuring anxiety and depression. In the present study, the total score was used for each subscale.

### 2.5. Assessment of pain intensity, TM and BE

In the present study, the pain VAS<sup>15</sup> was presented as a 10-cm straight horizontal line, numbered, with the words *no pain* at the left end and *worst possible pain* at the right end.

The visual analog scales of TM and BE, with 0 representing the absence of symptoms and 10 the maximum level of symptoms,<sup>16</sup> has been used in diverse adult populations.<sup>16,17</sup>

### 2.6. Assessment of PP

Physiological parameters such as heart rate (HR) and peripheral oxyhemoglobin saturation ( $\text{SpO}_2$ ) were assessed with a portable Rossmann SB220 Fingertip Pulse Oximeter (Rossmann InnoTec Corporation, Taipei, Taiwan) attached to the index finger of the left upper limb.

### 2.7. Statistical analysis

Data were analyzed statistically using descriptive statistics. Categorical variables were analyzed using the Chi-square test or Fisher's exact. Repeated measure data were analyzed by the Wilcoxon test and analysis of variance (ANOVA). Differences were considered to be statistically significant when  $p < 0.05$ .


## 3. Results

### 3.1. Characteristics of the participants

The study population included those with diseases of the cardiovascular system, as the admission's primary or secondary diagnosis (Table 1).

Thus, the sample consisted of 41 patients (Fig. 1), 23 (56%) of them male cardiovascular inpatients. Age ranged from 25 to 92 years (mean  $\pm$  SD:  $58 \pm 16.8$ ). Eleven (26.2%) patients were smokers. The sociodemographic, economic and religiosity characteristics of the cardiovascular inpatients are listed and compared in Table 2.

Participant characteristics at baseline were similar in both groups. Comparison of the results obtained for each group revealed a significant reduction in anxiety levels and in the TM in the group submitted to SP, as well as an increased  $\text{SpO}_2$ , and an improved sensation of well-being. HG subjects showed a reduction in the TM and improved BE (Table 3).



**Table 2**  
Sociodemographic, economic and religiousness characteristics of the patients (n = 41) in the groups studied.

		Control (n = 13)	SP (n = 14)	Sham (n = 14)	P
Gender <sup>a</sup>	Male	8 (61.5)	6 (42.9)	9 (64.3)	0.464
	Female	5 (38.5)	8 (57.1)	5 (35.7)	
Age (years) <sup>b</sup>		58 ± 15.7	60 ± 15.9	57 ± 19.7	0.464
Race/color <sup>a</sup>	White	8 (61.5)	6 (42.9)	7 (50.0)	0.621
	Not-White	5 (38.5)	8 (57.1)	7 (50.0)	
Marital Status <sup>a</sup>	Single	3 (23.1)	1 (7.1)	3 (21.4)	0.343
	Married/In union	7 (53.8)	10 (71.4)	7 (50.0)	
	Separated/Divorced	2 (15.4)	2 (14.3)	0 (0.0)	
	Widow/Widower	1 (7.7)	1 (7.1)	4 (28.6)	
Education <sup>a</sup>	<8years	10 (76.9)	9 (64.3)	7 (50.0)	0.529
	>8years	3 (23.1)	5 (35.7)	7 (50.0)	
Individual Wage <sup>a,c</sup>	No wage <sup>c</sup>	2 (15.4)	4 (28.6)	2 (14.3)	0.616
	Up to 1 minimum wage >1	6 (46.2)	7 (50.0)	7 (50.0)	
	Catholic	5 (38.5)	3 (21.4)	5 (35.7)	
Religious affiliation <sup>a</sup>	Evangelical	8 (61.5)	7 (50.0)	6 (42.8)	0.848
	Spiritist	0 (0.0)	1 (7.1)	2 (14.3)	
	No religion	4 ((30.8))	4 (28.6)	4 (28.6)	
Religiosousness <sup>d</sup> DUREL	RO	1 (7.7)	2 (14.3)	2 (14.3)	
	RNO	3 <sup>1-6</sup>	4 <sup>1-6</sup>	3 <sup>1-6</sup>	0.616
	RI	5 <sup>1-6</sup>	5.5 <sup>1-6</sup>	5 <sup>1-6</sup>	
		15 <sup>3-15</sup>	12 <sup>3-15</sup>	10.5 <sup>3-15</sup>	

SP, Spiritist 'passe'; RO, organizational religiosity; RNO, non-organizational religiosity; RI, intrinsic religiosity.

<sup>a</sup> n (%).

<sup>b</sup> mean (SD).

<sup>c</sup> The minimum wage at the time of data collection was R\$ 788.00.

<sup>d</sup> Median [minimum and maximum].

### 3.2. Assessment of anxiety and depression


The anxiety total scale scores were significantly reduced in the patients submitted to SP between the baseline and D3 ( $p=0.001$ ) and ( $p=0.003$ ) compared to HG and CG (Fig. 2, Table 3).

Depression total scores were reduced on the periods studied in the SP group ( $p=0.108$ ), although the difference was not sta-

tistically significant. When compared to SP, HG and CG, was not statistically different ( $p=0.858$ ).

### 3.3. Assessment of the TM and BE

The ANOVA-Friedman test revealed a significant reduction in the TM in the patients submitted to SP when comparing the D1



**Fig. 2.** Anxiety-D1, anxiety scores baseline; Anxiety-D3, anxiety scores on D3.


( $p=0.011$  on the D1 after compared to baseline), between the D1 and D2 ( $p=0.010$  on the D2 before compared to the D1 after), D2 ( $p=0.007$  at the before and after), between D2 and D3 ( $p=0.024$  on the D3 after compared to the D2 before), and, finally, the D3 ( $p=0.017$  at the before and after). There was a significant reduction in the TM in the patients submitted to HG between the D1 and D2 ( $p=0.028$  on the D2 before compared to the D1 after), and, between D2 and D3 ( $p=0.032$  on the D3 before compared to the D2 before and  $p=0.010$  on the D3 after compared to D2 before).

**Table 3**  
Clinical outcomes in patients (n=41) in the groups studied.

		Control Mean (SD)	SP Mean (SD)	Sham Mean (SD)
Anxiety	Baseline	8.62 ± 5.57	9.64 ± 6.69 <sup>a</sup>	7.92 ± 4.76
	After D3	8.00 ± 5.71 <sup>b</sup>	3.71 ± 3.49 <sup>a,b</sup>	7.92 ± 4.76 <sup>b</sup>
Depression	Baseline	7.92 ± 7.02	6.00 ± 5.71	6.69 ± 5.34
	After D3	7.69 ± 6.11	4.21 ± 3.98	6.31 ± 5.34
Muscle tension	Baseline	2.85 ± 2.48	3.71 ± 3.67 <sup>c</sup>	3.71 ± 3.45
	After D1	2.15 ± 2.38	1.07 ± 1.49 <sup>c,d</sup>	2.29 ± 2.70 <sup>h</sup>
	Before D2	3.46 ± 2.63	4.36 ± 3.6 <sup>d,e,f</sup>	4.86 ± 3.68 <sup>h,i,j</sup>
	After D2	3.08 ± 2.60	2.21 ± 2.69 <sup>e</sup>	3.64 ± 3.93
	Before D3	3.31 ± 2.59	3.00 ± 3.21 <sup>g</sup>	1.71 ± 3.10 <sup>i</sup>
	After D3	3.69 ± 2.39 <sup>k</sup>	1.43 ± 2.68 <sup>f,g,k</sup>	1.36 ± 2.62 <sup>j,k</sup>
Well-being	Baseline	7.54 ± 2.03	6.93 ± 2.70 <sup>l,m</sup>	7.21 ± 3.02 <sup>t</sup>
	After D1	7.85 ± 1.91 <sup>x</sup>	9.36 ± 0.95 <sup>n,p,x</sup>	7.50 ± 2.53 <sup>u,x</sup>
	Before D2	7.46 ± 2.15	6.43 ± 2.68 <sup>n,o,q</sup>	6.64 ± 2.98 <sup>u,v,w</sup>
	After D2	7.92 ± 2.02 <sup>y</sup>	9.00 ± 1.04 <sup>m,o,r,y</sup>	7.93 ± 3.0 <sup>v,y</sup>
	Before D3	7.15 ± 2.03	6.86 ± 2.63 <sup>p,r,s</sup>	8.29 ± 2.02
	After D3	7.38 ± 2.06 <sup>z</sup>	8.93 ± 1.86 <sup>p,q,s,z</sup>	8.93 ± 1.33 <sup>t,u,w,z</sup>
Heart rate	Baseline	75.08 ± 14.45	73.57 ± 9.15	76.31 ± 11.43
	After D1	74.38 ± 15.08	70.50 ± 13.20	75.69 ± 11.72
	Before D2	75.69 ± 14.13	72.64 ± 14.60	77.54 ± 12.39
	After D2	76.15 ± 12.72	70.00 ± 11.50	78.54 ± 11.6
	Before D3	74.46 ± 11.52	72.14 ± 13.83	77.23 ± 11.37
	After D3	72.62 ± 9.90	71.79 ± 11.83	76.08 ± 12.79
SpO <sub>2</sub>	Baseline	96.46 ± 2.50	94.00 ± 3.80 <sup>aa</sup>	95.85 ± 3.21
	After D1	95.54 ± 2.29	94.07 ± 3.14 <sup>ab</sup>	96.15 ± 2.07
	Before D2	95.15 ± 3.02	95.93 ± 2.36	96.31 ± 2.78
	After D2	95.38 ± 3.04	95.86 ± 2.31	95.15 ± 2.79
	Before D3	95.62 ± 2.10	96.29 ± 1.72 <sup>aa,ab</sup>	96.15 ± 2.47
	After D3	95.62 ± 2.33	95.71 ± 2.05	95.23 ± 2.16
Pain	Baseline	1.00 ± 2.40	2.43 ± 3.36	2.00 ± 3.02
	After D1	0.92 ± 2.52	1.07 ± 1.81	2.15 ± 3.21
	Before D2	1.46 ± 2.86	2.43 ± 3.36	1.46 ± 3.04
	After D2	1.31 ± 2.72	2.21 ± 3.44	0.69 ± 1.97
	Before D3	1.00 ± 2.65	1.43 ± 2.73	1.38 ± 2.63
	After D3	1.31 ± 2.78	0.93 ± 2.20	0.62 ± 2.21

SP, Spiritist "passe"; SpO<sub>2</sub>, peripheral oxyhemoglobin saturation.


a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab  $p < 0.05$ .



**Fig. 3.** TMA, muscle tension before the interventions; TMD, muscle tension after the interventions.

The greater reduction scores in the TM was seen in the SP group compared to HG and CG ( $p=0.003$  on the D3 in the difference between before and after interventions). The results might be seen in Fig. 3, Table 3.

The values of well-being reported by the patients were significantly increased among those submitted to SP when comparing the D1 ( $p=0.003$  on the D1 after compared to baseline), between the D1 and D2 ( $p=0.016$  on the D2 after compared to baseline and  $p=0.005$  on the D2 before compared to on the D1 after), the D2 ( $p=0.003$  at the before and after), between D1 and D3 ( $p=0.003$



**Fig. 4.** BEA, well-being before the interventions; BED, well-being after the interventions.

on the D3 before compared to on the D1 after), between D2 and D3 ( $p=0.020$  on the D3 after compared to D2 before and  $p=0.006$  on the D3 before compared to the D2 after), and, finally, the D3 ( $p=0.012$  at the before and after). Until, significantly increased of BE in the patients of HG were observed between the D1 and D3 ( $p=0.045$  on the D3 after compared to baseline and  $p=0.032$  on the D3 after compared to on the D1 after), the D2 ( $p=0.017$  at the before and after) and, between D2 and D3 ( $p=0.016$  on the D3 after compared to D2 before).

The greater increase scores in the BE was observed in the SP group compared to the HG ( $p=0.003$  on the day 1,  $p=0.016$  on the day 2 and  $p=0.011$  on the day 3 in the difference between before and after interventions), showing that these patients felt a better well-being (Fig. 4, Table 3).

#### 3.4. Assessment of physiological parameters

The SP group showed a significant increase in SpO<sub>2</sub> scores during the periods studied, between the D1 and D3 ( $p=0.028$  on the D3 before compared to baseline and  $p=0.013$  on the D3 before compared to the D1 after), demonstrating improved SpO<sub>2</sub> throughout the study (Table 3).

The SP group showed lower HR values after the interventions, although the difference was not statistically significant ( $p=0.302$ ).

The pain scores did not differ significantly between the periods analyzed in CG ( $p=0.169$ ), SP ( $p=0.149$ ), or HG ( $p=0.516$ ).

## 4. Discussion

Cardiovascular inpatients who received SP reported a significantly greater reduction in anxiety scores, TM and increase in the SpO<sub>2</sub>, and BE after receiving 3 days of therapy.

The finding of significantly greater anxiety relief reported by SP subjects is consistent with results observed by studies.<sup>18–20</sup> The persistence of anxiety symptoms may lead to functional impairment, reducing the quality of life and negatively affecting the cardiovascular prognosis.<sup>21–24</sup>

The reduction in depression scores was detected in individuals receiving SP in agreement with the findings obtained in recent studies evaluating SP.<sup>25,26</sup> It has been reported that depression is a risk factor for poor outcomes among patients who might not be adhering to medical advice.<sup>27</sup> The Spiritist “passe” is considered an immediate transmission of energy from the Spiritist healer to the receptor subject.<sup>11</sup> Homeostasis and neuroendocrine circuits involved in the depression<sup>28</sup> might be improved by the reception of magnetic energy provided by this approach.<sup>18,29</sup>

In this study, there was a reduction in the TM and increase in the BE in the SP and HG. However, there were effects of greater magnitude in the SP group. Our findings agree with those in the literature, which describes that the administration of Spiritist “passe” may bring direct and positive impacts over the human being behavior,<sup>18</sup> denoting the influence of the spiritual energy on physical health.

The present results showed a significant increase in SpO<sub>2</sub> in the SP throughout the study. A recent systematic review suggest that biofield interventions can generate salutogenic effects in cardiovascular function in coronary patients.<sup>30</sup>

A reduction in HR was observed here after SP, although the difference was non significant. Carneiro et al. observed a reduction in respiratory rate and HR in neonates submitted to SP.<sup>31</sup>

The pain scores did not differ significantly after the interventions, even in patients with ACS ( $p=0.615$ ), which could be explained by the small number of patients of this subgroup or because they were receiving specific clinical therapy. A systematic review by Jain and Mills<sup>32</sup> suggested that biofield therapies demonstrated strong evidence for reducing self-reported pain intensity in a variety of patients.

Moreover, this study is the first in assessing the Spiritist “passe” in cardiovascular inpatients. It should be pointed out the fact that no patient reported adverse effects. The Spiritist “passe”, as a type of aid invariably applicable with no contraindication, is always valuable for the treatment of any class of patients, from small children to elderly individuals.<sup>33</sup>

The study had limitations such as the size of the sample, it was addressed only to cardiovascular inpatients and our results may not be extended to other different population. Other limitations were the lack of follow up after the interventions and the fact that despite the studied sample has individuals with different religious and belief system, all of them are Christian due to the characteristics of Brazilian population religiousness.

In addition, further studies are needed with larger samples, and exploring the nature and the physiological basis of healing with biofield therapy. It would also be of interest the long term follow up studies in order to assess the safety of the therapy in question.

## 5. Conclusion

The present results suggest that SP was effective in reducing anxiety, muscle tension, and consequently improving SpO<sub>2</sub> and well-being in cardiovascular inpatients.

#### Authors' contributions

Carneiro EM has made substantial contributions to conception and design, acquisition of data, and interpretation of data; has been involved in drafting the manuscript; and has given final approval of the version to be published. Barbosa LP, Terra Junior JA, Martins CJP and Resende LAPR involved in revising the manuscript critically for important intellectual content; and has given final approval of the version to be published. Borges MF has been involved in drafting the manuscript; has been involved in revising the manuscript critically for important intellectual content; and has given final approval of the version to be published. Modesto D has made substantial contributions to acquisition of data and has given final approval of the version to be published. Marson JM has made contributed to statistical analysis, has been involved in revising the manuscript critically for important intellectual content; and has given final approval of the version to be published. All authors have read and approved the final manuscript.

## Conflict of interest

Authors declare that there are no conflicts of interest related to the publication of this work.

## Acknowledgements

Sincere thanks for the contribution of Núcleo de Apoio ao Pesquisador—NAP of the Gerência de Ensino e Pesquisa HC-UFTM, volunteers, Guilherme Henrique Bandeira, and Sebastião Tostes Junior in the present project.

## References

1. Jiang W, Kuchibhatla M, Cuffe MS, et al. Prognostic value of anxiety and depression in patients with chronic heart failure. *Circulation*. 2004;22:3452–3456.
2. Johansson I, Swahn E, Strömberg A. Manageability, vulnerability and interaction: a qualitative analysis of acute myocardial infarction patients' conceptions of the event. *Eur J Cardiovasc Nurs*. 2007;3:184–191.
3. Wells KB, Rogers W, Burnam A, Greenfield S, Ware Jr JE. How the medical comorbidity of depressed patients differs across health care settings: results from the Medical Outcomes Study. *Am J Psychiatry*. 1991;12:1688–1696.
4. Bruce DG, Casey GP, Grange V, et al. Fremantle cognition in diabetes study cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the fremantle cognition in diabetes Study. *Diabetes Res Clin Pract*. 2003;1:59–67.
5. Soderlin MKM, Hakala M, Nieminen P. Anxiety and depression in a community-based rheumatoid arthritis population. *Scand J Rheumatol*. 2000;3:177–213.
6. Carney RM, Blumenthal JA, Fredland KE, ENRICHD Investigators, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. *Psychosom Med*. 2004;6:466–474.
7. Sardinha A, Araújo CGS, Silva ACO, Nardi AE. Prevalência de transtornos psiquiátricos e ansiedade relacionada à saúde em coronariopatas participantes de um programa de exercício supervisionado. *Archiv Clin Psychiatry*. 2011;2:2011.
8. Gomes VM, Silva MJ, Araújo EA. Efeitos gradativos do toque terapêutico na redução da ansiedade de estudantes universitários. *Rev Bras Enferm*. 2008;61:841–846.
9. Vasques CI, Santos DS, Carvalho EC. Tendências da pesquisa envolvendo o uso do toque terapêutico como uma estratégia de enfermagem. *Acta Paulista de Enfermagem*. 2011;24:712–714.
10. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States. *Natl Health Stat Rep*. 2008;12:1–23.
11. Lucchetti AL, Peres MF, Vallada HP, Lucchetti G. Spiritual treatment for depression in Brazil: an experience from Spiritism. *Explore (NY)*. 2015;11:377–386.
12. Nobre M., O Passe Como Cura Magnética. São Paulo, 4<sup>a</sup> edição, 2011.
13. Lucchetti G, et al. Effect of Spiritist "passe" (Spiritual healing) on growth of bacterial cultures. *Complement Ther Med*. 2013;21:627–632.
14. Botega N, Bio M, Zomignani M, Garcia C, Pereira W. Transtornos do humor em enfermaria de clínica médica e validação de escala de medida (HAD) de ansiedade e depressão. *Revista Saúde Pública*. 1995;5:355–363.
15. Huskisson EC. Measurement of pain. *Lancet*. 1974;2:1127–1131.
16. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. *Res Nurs Health*. 1990;4:227–236.
17. Oliveira RMJ. Efeitos da prática do Reiki sobre aspectos psicofisiológicos e de qualidade de vida de idosos com sintomas de estresse: estudo placebo e randomizado Tese (Doutorado) –Universidade Federal de São Paulo, Escola Paulista de Medicina, Programa de Pós-Graduação em Psicobiologia, 2013.
18. Carneiro EM, Moraes GV, Terra GA. Effectiveness of spiritist "Passe" (Spiritual healing) on the psychophysiological parameters in hospitalized patients. *Adv Mind-Body Med*. 2016;30(3):4–10.
19. Cavalcante RS, Banin VB, Paula NAMR. Effect of the Spiritist passe energy therapy in reducing anxiety volunteers: a randomized controlled trial. *Complement Ther Med*. 2016;27:18–24.
20. Komorovsky R, Desideri A, Rozbowsky P, Sabbadin D, Celegon L, Gregori D. Quality of life and behavioral compliance in cardiac rehabilitation patients: a longitudinal survey. *Int J Nurs Stud*. 2008;7:979–985.
21. Frasure-Smith N, Lesperance F. Recent evidence linking coronary heart disease and depression. *Can J Psychiatry*. 2006;12:730–737.
22. Frasure-Smith N, Lesperance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. *Arch Gen Psychiatry*. 2008;1:62–71.
23. Katerndahl D. Panic & plaques: panic disorder & coronary artery disease in patients with chest pain. *J Am Board Fam Pract*. 2004;2:114–126.
24. Furze G, Lewin RJP, Murberg T, Bull P, Thompson DR. Does it matter what patients think? The relationship between changes in patients' beliefs about angina and their psychological and functional status. *J Psychosom Res*. 2005;5:323–329.
25. Rein G. Bioinformation within the biofield: beyond bioelectromagnetics. *J Altern Complement Med*. 2004;10:59–68.
26. Rubik B. Measurement of the human biofield. In: Freeman, Editora Mosby's complementary and alternative medicine: a research based approach. St. Louis: Mosby/Elsevier; 2009:555–573.
27. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med*. 2000;14:2101–2107.
28. Esperidião-Antônio Esperidião-Antônio, Colombo MM, Monteverde DT, et al. Neurobiologia das emoções. *Rev Psiq Clín*. 2008;35:55–65.
29. Lucchetti G, Lucchetti AL, Bassi RM, Nobre MR. Complementary spiritist therapy: systematic review of scientific evidence. *Evid Based Complement Altern Med*. 2011;835945.
30. Jain S, Hammerschlag R, Mills P, et al. Clinical studies of biofield therapies: summary, methodological challenges, and recommendations. *Glob Adv Health Med*. 2015;4:58–66.
31. Carneiro EM, Barbosa LP, Bittencourt AC, et al., Effects of Spiritist passe (Spiritual healing) on serum cortisol levels, pain, physiological parameters and length of stay in newborns: randomized clinical trials, 7<sup>a</sup> Jornada Pernambucana de Saúde e Espiritualidade e Congresso Nacional do Departamento Acadêmico de Pernambuco, 2016.
32. Jain S, Mills PJ. Biofield therapies: helpful or full of hype? A best evidence synthesis. *Int J Behav Med*. 2010;1:1–16.
33. Xavier FC, Mecanismo da Mediunidade. Pelo Espírito Emmanuel. Rio de Janeiro, editora 26, FEB; 2010.